NO971704L - Fremgangsmåte for reversering av multimedikamantsesistens - Google Patents

Fremgangsmåte for reversering av multimedikamantsesistens

Info

Publication number
NO971704L
NO971704L NO971704A NO971704A NO971704L NO 971704 L NO971704 L NO 971704L NO 971704 A NO971704 A NO 971704A NO 971704 A NO971704 A NO 971704A NO 971704 L NO971704 L NO 971704L
Authority
NO
Norway
Prior art keywords
reversing
resistance
multimedia
procedure
dihydronaphthalene
Prior art date
Application number
NO971704A
Other languages
English (en)
Norwegian (no)
Other versions
NO971704D0 (no
Inventor
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
Ii James Jacob Starling
Mark Alan Winter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO971704D0 publication Critical patent/NO971704D0/no
Publication of NO971704L publication Critical patent/NO971704L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO971704A 1994-10-14 1997-04-14 Fremgangsmåte for reversering av multimedikamantsesistens NO971704L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32317694A 1994-10-14 1994-10-14
PCT/US1995/013036 WO1996011677A1 (en) 1994-10-14 1995-10-13 Methods for treating resistant tumors

Publications (2)

Publication Number Publication Date
NO971704D0 NO971704D0 (no) 1997-04-14
NO971704L true NO971704L (no) 1997-05-13

Family

ID=23258042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971704A NO971704L (no) 1994-10-14 1997-04-14 Fremgangsmåte for reversering av multimedikamantsesistens

Country Status (14)

Country Link
US (2) US6121292A (de)
EP (2) EP0709090A3 (de)
JP (1) JPH10512544A (de)
CN (1) CN1168631A (de)
AU (1) AU702301B2 (de)
CA (1) CA2202661A1 (de)
CZ (1) CZ113797A3 (de)
FI (1) FI971568A (de)
HU (1) HUT77604A (de)
IL (1) IL115582A0 (de)
MX (1) MX9702700A (de)
NO (1) NO971704L (de)
WO (1) WO1996011677A1 (de)
ZA (1) ZA958688B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08253417A (ja) * 1995-02-28 1996-10-01 Eli Lilly & Co 脳又はｃｎｓのエストロゲン陽性腫瘍抑制用製剤
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
CA2236543A1 (en) * 1995-11-07 1997-05-15 Alan David Palkowitz Methods for treating resistant tumors
CA2206752A1 (en) 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
CA2214922A1 (en) * 1996-09-27 1998-03-27 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
NZ336381A (en) 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
JP2002514217A (ja) 1997-04-30 2002-05-14 イーライ・リリー・アンド・カンパニー 抗血栓物質
EP0980367A4 (de) 1997-04-30 2003-03-19 Lilly Co Eli Antithrombosemittel
US6271227B1 (en) 1997-04-30 2001-08-07 Eli Lilly And Company Antithrombotic Agents
EP1027051B1 (de) 1997-04-30 2005-01-05 Eli Lilly And Company Antithrombotische mittel
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
CA2346029A1 (en) * 1998-10-02 2000-04-13 Anthony R. Imondi Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
CA2287549A1 (en) * 1998-10-28 2000-04-28 Jefferson Ray Mccowan Antithrombotic agents
AU2998900A (en) * 1999-02-19 2000-09-04 Leslee S. Brooks Zinc chloride in treating skin diseases
WO2002020478A1 (en) * 2000-08-24 2002-03-14 Dublin City University N-benzylindole-3-acetic acid derivatives for use in the treatment of drug resistan cancer
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (ko) * 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019832A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
FR2913017A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
US9980947B2 (en) * 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
CN108129375B (zh) * 2018-01-30 2020-04-28 中山大学 化合物及其制备方法与在制备肿瘤耐药逆转剂中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
IL111287A0 (en) * 1993-10-15 1994-12-29 Lilly Co Eli Methods for treating resistant neoplasms
JPH09507071A (ja) * 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
EP0736007A4 (de) * 1993-12-21 1997-03-19 Lilly Co Eli Nicht-peptidische tachykinin rezeptor antagonisten
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy

Also Published As

Publication number Publication date
FI971568A (fi) 1997-06-12
EP0709090A3 (de) 1996-08-28
FI971568A0 (fi) 1997-04-14
EP0709090A2 (de) 1996-05-01
AU702301B2 (en) 1999-02-18
MX9702700A (es) 1997-06-28
IL115582A0 (en) 1996-01-19
US6124311A (en) 2000-09-26
CN1168631A (zh) 1997-12-24
ZA958688B (en) 1997-04-14
AU3829895A (en) 1996-05-06
EP0820769A2 (de) 1998-01-28
NO971704D0 (no) 1997-04-14
JPH10512544A (ja) 1998-12-02
CA2202661A1 (en) 1996-04-25
HUT77604A (hu) 1998-06-29
WO1996011677A1 (en) 1996-04-25
EP0820769A3 (de) 1998-08-19
US6121292A (en) 2000-09-19
CZ113797A3 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
NO971704L (no) Fremgangsmåte for reversering av multimedikamantsesistens
AR007609A1 (es) Una composicion farmaceutica
Erl et al. Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands
EA199800667A1 (ru) Новые фенантридины
BR0015491A (pt) Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
ES2133714T3 (es) Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
EA200000351A1 (ru) Лечение кондуктивных нарушений
ES2154789T3 (es) Procedimiento para la fabricacion de xileno.
ES2174895T3 (es) Combinaciones metalicas complejas con contenido en carbenos heterociclicos.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
ES540645A0 (es) Aparato para el tratamiento del plasma.
NO990701L (no) Behandling av vanlig forkj°lelse eller allergisk rhinitt
Agnew et al. Isoflurane and coronary heart disease
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
ES2099289T5 (es) Procedimiento para la ciclodimerizacion de 1,3-butadienos a 4-vinilciclohexenos.
EA199800867A1 (ru) Соединения тетрагидробетакарболина
CO5160295A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri
NO832720L (no) Fremgangsmaate for isomerisering av styrenoksyd til fenylaldehyd.
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
DE69327113D1 (de) Methode zum erzeugen von analgie mittels neurotrophine
NO985676D0 (no) Forbindelser med colchicinstruktur, deres anvendelse som legemidler og blandinger som inneholder dem
DK0471259T3 (da) Phenylsulfonamid-substituerede pyridinalken- og -aminooxyalkancarboxylsyre-derivater